On September 30, Kodiak Sciences Inc. rose 6.48% in regular trading, trading at $96.955 per share, with turnover of approximately $56.01 million. The stock continued its upward trajectory following a landmark clinical data readout earlier this week.

The sustained rally stems from the company's announcement that its two experimental eye drugs, Zenkuda and tabirafusp-ted, both met primary endpoints in a Phase 3 study in patients with wet age-related macular degeneration (wet AMD). Both treatments achieved non-inferiority in vision gains compared with aflibercept during the first year, and 54% of patients maintained a six-month dosing interval through the first year under the study's retreatment criteria. The initial data release had driven the stock up over 146% on September 28 with $1.57 billion in turnover, reflecting the significance of the clinical milestone.

Looking ahead, the company plans to submit Zenkuda data from five positive Phase 3 studies to regulatory authorities in Q4, covering wet AMD, diabetic retinopathy, and macular edema following retinal vein occlusion — broadening its potential commercial opportunity across multiple high-prevalence retinal disease indications.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)